Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M39.0Revenue (TTM) $M20.6Net Margin (%)-38.0Altman Z-Score-5.4
Enterprise Value $M4.2EPS (TTM) $-0.9Operating Margin %-39.1Piotroski F-Score6
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-38.0Higher ROA y-yY
Price/Book0.910-y EBITDA Growth Rate %-20.4Quick Ratio11.7Cash flow > EarningsY
Price/Sales1.95-y EBITDA Growth Rate %-13.8Current Ratio11.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-15.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-16.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.2ROIC % (ttm)-93.3Gross Margin Increase y-yY

Gurus Latest Trades with VICL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VICLJohn Rogers 2016-03-31 Reduce-0.01%$3.05 - $4.53
($3.66)
$ 4.2416%Reduce -20.34%553,776
VICLJohn Rogers 2015-12-31 Reduce$3.5 - $5.34
($4.13)
$ 4.243%Reduce -6.51%695,218
VICLJohn Rogers 2015-09-30 Reduce$4.58 - $7
($6.14)
$ 4.24-31%Reduce -0.32%743,627
VICLJohn Rogers 2015-06-30 Add$7 - $14.8
($9.93)
$ 4.24-57%Add 7.21%746,052
VICLJohn Rogers 2015-03-31 Add$8.55 - $11.7
($10.17)
$ 4.24-58%Add 7.34%695,895
VICLJohn Rogers 2014-12-31 Add0.01%$10 - $12.5
($11.22)
$ 4.24-62%Add 10.25%648,322
VICLGeorge Soros 2014-09-30 Sold Out $11.2 - $13.1
($12.34)
$ 4.24-66%Sold Out0
VICLJohn Rogers 2014-09-30 Add$11.2 - $13.1
($12.34)
$ 4.24-66%Add 1.48%588,071
VICLGeorge Soros 2014-06-30 Buy $11.2 - $13.5
($11.96)
$ 4.24-65%New holding5,818
VICLJohn Rogers 2014-03-31 Reduce-0.02%$11.8 - $17.2
($14.18)
$ 4.24-70%Reduce -17.94%579,509
VICLJohn Rogers 2013-12-31 Add0.03%$10.15 - $14.9
($12.01)
$ 4.24-65%Add 39.31%706,210
VICLJohn Rogers 2013-09-30 Reduce$11.9 - $42.6
($23.8)
$ 4.24-82%Reduce -1.28%506,924
VICLJohn Rogers 2013-06-30 Add0.13%$29.3 - $42.2
($35.16)
$ 4.24-88%Add 93.26%513,482
VICLJohn Rogers 2013-03-31 Add0.08%$29.1 - $42.6
($35.48)
$ 4.24-88%Add 71.60%265,697
VICLJohn Rogers 2012-12-31 Add0.03%$27.4 - $43.2
($32.97)
$ 4.24-87%Add 49.50%154,836
VICLJohn Rogers 2012-09-30 Add0.01%$33 - $45.8
($36.94)
$ 4.24-89%Add 8.77%103,566
VICLJohn Rogers 2012-06-30 Add0.01%$28 - $36
($30.67)
$ 4.24-86%Add 8.55%95,219
VICLJohn Rogers 2012-03-31 Add0.01%$30.2 - $44.9
($34.68)
$ 4.24-88%Add 26.34%87,719
VICLJohn Rogers 2011-12-31 Add$22.9 - $46.9
($36.28)
$ 4.24-88%Add 7.48%69,430
VICLJohn Rogers 2011-09-30 Add$24.3 - $52
($37.92)
$ 4.24-89%Add 11.80%64,596
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VICL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VICL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2016-07-11Sell54$4.46-4.93view
MERTON ROBERT CDirector 2016-06-14Buy9,000$4.34-2.3view
SAMANT VIJAY BPresident & CEO 2016-06-09Buy15,700$4.72-10.17view
DOUGLAS R GORDONDirector 2016-06-06Buy10,078$4.41-3.85view
LYONS GARY ADirector 2016-06-03Buy7,078$4.39-3.42view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2016-03-15Sell88$41-89.66view
SAMANT VIJAY BPresident & CEO 2016-03-03Sell375$36-88.22view
Ramos Anthony AlanVP, Chief Accounting Officer 2016-02-19Sell75$33-87.15view
Ramos Anthony AlanVP, Chief Accounting Officer 2016-01-25Sell2$35-87.89view
SAMANT VIJAY BPresident & CEO 2016-01-12Sell597$35-87.89view

Quarterly/Annual Reports about VICL:

News about VICL:

Articles On GuruFocus.com
CEOs Sell Vical, PhotoMedex, E.W. Scripps, Smart & Final Stores Jan 18 2016 
Red Hat (RHT) and Five Below (FIVE) Strong Performance Metrics; Vical (VICL) Targets Multi-billion S Mar 26 2015 
John Rogers Comments on Vical Feb 26 2014 
Kids Decide on Dolls or Devices - JAKK, Others 70% Off Sep 17 2013 
Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI Jan 21 2013 
Vical Inc. Insiders Boost Shares after Company’s NASDAQ Listing Gets Upgrade Jan 17 2013 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Vical Inc. (VICL) CEO Vijay B Samant buys 1,000 Shares Jan 20 2011 
Vical Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vical Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine Jun 21 2016
Vical’s Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in... Jun 20 2016
Vical’s Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in... Jun 20 2016
Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference Jun 13 2016
Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference Jun 13 2016
Vical Provides VL-2397 Updates at BIO International Convention May 31 2016
Vical Provides VL-2397 Updates at BIO International Convention May 31 2016
VICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of... May 25 2016
Vical, Inc. :VICL-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
VICAL INC Financials May 18 2016
Q1 2016 Vical Inc Earnings Release - Before Market Open May 09 2016
Vical Reports First Quarter 2016 Financial Results May 09 2016
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 09 2016
Vical reports 1Q loss May 09 2016
Vical reports 1Q loss May 09 2016
Vical Reports First Quarter 2016 Financial Results May 09 2016
Investor Calendar Invites You to the Vical First Quarter 2016 Earnings Webcast Live on Monday, May... May 06 2016
Vical Announces News Release and Conference Call Schedule for First Quarter 2016 Financial Results May 02 2016
Vical Announces News Release and Conference Call Schedule for First Quarter 2016 Financial Results May 02 2016
FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis Mar 30 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)